

heart

Helping Expand Access
to Reproductive Therapy
by FERRING PHARMACEUTICALS

When their road to parenthood needs a helping hand, *take heart.*

- ▶ Find out which of your in vitro fertilization (IVF) patients may be eligible for financial assistance.

With Ferring, getting them there tomorrow means setting things right today.

We understand the impact that COVID-19 has had on both your patients and your practice. Ferring is committed to building healthy families by developing innovative fertility treatments and expanding access to IVF therapies. One part of that mission is the HEART programs, which continue to help ease some of the financial burden for patients, including those affected by COVID-19, who are seeking fertility treatment.

Financial support in response to COVID-19:



For patients who have been prescribed select Ferring fertility medications

Cash-paying and commercially insured patients may be eligible to receive a \$200 rebate for out-of-pocket costs for purchases of select Ferring fertility medications made after June 1, 2020. Terms and conditions apply.

\$200 REBATE

► To request additional information and for full program terms and conditions, please email oneheart@envisionrx.com



For patients whose cycles were canceled due to COVID-19

This program provides medication replacement for eligible cash-paying patients, or up to \$250 in assistance towards co-pay costs for eligible commercially insured patients whose controlled ovarian stimulation ("COS") cycles were canceled as a result of COVID-19 and who are initiating a new treatment cycle. Terms and conditions apply.

**MEDICATION
REPLACEMENT**

\$250 CO-PAY
ASSISTANCE

▶ **To request additional information and for full program terms and conditions, please email heartfelt@envisionrx.com**

Program ends December 31, 2020.



For patients who elect to freeze their eggs

This program provides a discounted price for MENOPUR for eligible cash-paying patients who are undergoing controlled ovarian stimulation ("COS") for planned oocyte cryopreservation. This discount may be available for eligible patients with a minimum initial prescription for 25 vials of MENOPUR and a signed and submitted physician attestation form. Terms and conditions apply.

Menopur[®]
(menotropins for injection)

DISCOUNTED PRICE

▶ **To request additional information and for full program terms and conditions, please email hearttomorrow@envisionrx.com**

Indication

MENOPUR[®] (menotropins for injection)

MENOPUR[®] (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.

Important Safety Information

MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR.

Please see Important Safety Information continued on the last page and [full Prescribing Information for MENOPUR](#).

Support beyond COVID-19

A legacy of helping your patients prepare for and respond to some of life's most challenging times.



For patients seeking to freeze their eggs prior to cancer treatment

This program provides select **fertility medications at no cost** for eligible patients. Qualifying patients must be female, be a US citizen or permanent resident, have received a diagnosis of cancer, and have received no chemotherapy within the previous 6 months. Oncologist and reproductive endocrinologist are required to determine that fertility preservation treatment is medically appropriate.

- ▶ **For more information and eligibility, call 888-347-3415. For residents of Arkansas, Massachusetts, or New Jersey, please call 877-252-0553.**

Terms and conditions apply.



For veterans and their spouses

This program helps eligible veterans and their spouses get select **fertility medications at no cost**. Eligible patients include those who are medically separated from active duty, who are Department of Defense Category 2 or 3 veterans,* with a service-related injury resulting in infertility and requiring assisted reproduction, or patients and/or spouses with no insurance coverage for IVF medications. Must be residents of the 50 United States or the District of Columbia.

- ▶ **For more information and eligibility, call 1-800-515-DRUG (3748).**

Terms and conditions apply.

*Category 2 veterans include those with a serious injury or illness, who are unlikely to return to duty within a time specified by his or her Military Department, and who may be medically separated from the military. Category 3 veterans include those who have a severe or catastrophic injury or illness, who are highly unlikely to return to duty, and who most likely will be medically separated from the military.

Indication

MENOPUR® (menotropins for injection)

MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.

Important Safety Information

MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.

MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.

The most common adverse reactions ($\geq 2\%$) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

Please see [full Prescribing Information for MENOPUR](#).